On #WorldCMLDay, MPP is pleased to join @themaxfoundation.org in the Philippines.
The country is among those beginning to benefit from MPP-enabled generic nilotinib through our Novartis licence.
Innovation only matters if it reaches people.
🔗 tli.sh/nTgEU
The country is among those beginning to benefit from MPP-enabled generic nilotinib through our Novartis licence.
Innovation only matters if it reaches people.
🔗 tli.sh/nTgEU
September 22, 2026 at 11:18 AM
On #WorldCMLDay, MPP is pleased to join @themaxfoundation.org in the Philippines.
The country is among those beginning to benefit from MPP-enabled generic nilotinib through our Novartis licence.
Innovation only matters if it reaches people.
🔗 tli.sh/nTgEU
The country is among those beginning to benefit from MPP-enabled generic nilotinib through our Novartis licence.
Innovation only matters if it reaches people.
🔗 tli.sh/nTgEU
More from #SOHO2026! Frontline 2nd-generation TKIs (dasatinib/nilotinib) show significantly more durable disease control than imatinib in Ph+ ALL
High baseline disease burden (hemoglobin < 8 g/dL, LDH ≥ 691 U/L, higher BCR::ABL1) independently predicted worse outcomes.
More: https://bit.ly/46kVhAB
High baseline disease burden (hemoglobin < 8 g/dL, LDH ≥ 691 U/L, higher BCR::ABL1) independently predicted worse outcomes.
More: https://bit.ly/46kVhAB
September 11, 2026 at 8:09 PM
More from #SOHO2026! Frontline 2nd-generation TKIs (dasatinib/nilotinib) show significantly more durable disease control than imatinib in Ph+ ALL
High baseline disease burden (hemoglobin < 8 g/dL, LDH ≥ 691 U/L, higher BCR::ABL1) independently predicted worse outcomes.
More: https://bit.ly/46kVhAB
High baseline disease burden (hemoglobin < 8 g/dL, LDH ≥ 691 U/L, higher BCR::ABL1) independently predicted worse outcomes.
More: https://bit.ly/46kVhAB
Chronic Myeloid Leukaemia Developing During Long-Term Alectinib Therapy Successfully Managed With Concomitant Nilotinib: A Case Report
onlinelibrary.wiley.com/doi/10.1002/...
onlinelibrary.wiley.com/doi/10.1002/...
<em>Respirology Case Reports</em> | APSR Respiratory Medicine Journal | Wiley Online Library
We report a case of chronic myeloid leukaemia (CML) diagnosed during long-term alectinib therapy in a patient with ALK-positive non-small cell lung cancer, in whom CML was confirmed by the presence…
onlinelibrary.wiley.com
September 3, 2026 at 3:00 AM
Chronic Myeloid Leukaemia Developing During Long-Term Alectinib Therapy Successfully Managed With Concomitant Nilotinib: A Case Report
onlinelibrary.wiley.com/doi/10.1002/...
onlinelibrary.wiley.com/doi/10.1002/...
Improvement of in vitro and in vivo properties of nilotinib-flavonoid drug-drug cocrystals: synergistic effect https://doi.org/10.1016/j.jddst.2026.108817 #Cocrystals
August 22, 2026 at 2:36 PM
Improvement of in vitro and in vivo properties of nilotinib-flavonoid drug-drug cocrystals: synergistic effect https://doi.org/10.1016/j.jddst.2026.108817 #Cocrystals
4/7 Two additional Phase 4 completions in GIST and CML patients, plus Phase 2 and Phase 3 progression in nilotinib treatment-free remission and pediatric asthma indications, rounded out a multi-indication pipeline update.
August 21, 2026 at 1:25 PM
4/7 Two additional Phase 4 completions in GIST and CML patients, plus Phase 2 and Phase 3 progression in nilotinib treatment-free remission and pediatric asthma indications, rounded out a multi-indication pipeline update.
"Precis som med Dasynoc är det Xsprays HyNap-teknologi som gör det möjligt att omvandla substansen (nilotinib) till en stabil amorf form, vilket löser Tasignas största begränsningar" enl Google
August 18, 2026 at 9:34 AM
"Precis som med Dasynoc är det Xsprays HyNap-teknologi som gör det möjligt att omvandla substansen (nilotinib) till en stabil amorf form, vilket löser Tasignas största begränsningar" enl Google
Jorge Cortes, MD, discusses the @FDA.gov approval of orally disintegrating nilotinib tablets for patients with chronic myeloid leukemia #leusm #hematology #oncology www.onclive.com/view/what-do...
What Does the FDA Approval of Orally Disintegrating Nilotinib Tablets Mean for CML Practice? | OncLive
Jorge Cortes, MD, discusses the FDA approval of orally disintegrating nilotinib tablets for patients with chronic myeloid leukemia.
www.onclive.com
August 12, 2026 at 1:26 PM
Jorge Cortes, MD, discusses the @FDA.gov approval of orally disintegrating nilotinib tablets for patients with chronic myeloid leukemia #leusm #hematology #oncology www.onclive.com/view/what-do...
T315I 之後不能換 bosutinib
T315I 是 gatekeeper 突變，imatinib、dasatinib、nilotinib、bosutinib 全部無效。
可用的只有 ponatinib，或走 asciminib 這條變構抑制的路。
Kinase domain 點突變是 TKI 治療下復發的主因，復發時務必做突變分析。
#血液專科
https://hema-2026.hsiehting.com/q/113-024
T315I 是 gatekeeper 突變，imatinib、dasatinib、nilotinib、bosutinib 全部無效。
可用的只有 ponatinib，或走 asciminib 這條變構抑制的路。
Kinase domain 點突變是 TKI 治療下復發的主因，復發時務必做突變分析。
#血液專科
https://hema-2026.hsiehting.com/q/113-024
August 3, 2026 at 12:21 PM
T315I 之後不能換 bosutinib
T315I 是 gatekeeper 突變，imatinib、dasatinib、nilotinib、bosutinib 全部無效。
可用的只有 ponatinib，或走 asciminib 這條變構抑制的路。
Kinase domain 點突變是 TKI 治療下復發的主因，復發時務必做突變分析。
#血液專科
https://hema-2026.hsiehting.com/q/113-024
T315I 是 gatekeeper 突變，imatinib、dasatinib、nilotinib、bosutinib 全部無效。
可用的只有 ponatinib，或走 asciminib 這條變構抑制的路。
Kinase domain 點突變是 TKI 治療下復發的主因，復發時務必做突變分析。
#血液專科
https://hema-2026.hsiehting.com/q/113-024
Asciminib 的機轉定位
它是 STAMP 抑制劑（Specifically Targeting the ABL Myristoyl Pocket），結合在肉豆蔻醯結合口袋，屬變構（allosteric）抑制。
傳統 TKI（imatinib、dasatinib、nilotinib、bosutinib、ponatinib）則競爭 ATP 結合位。
機轉不同，所以抗藥突變譜也不同。
#血液專科
https://hema-2026.hsiehting.com/q/114-031
它是 STAMP 抑制劑（Specifically Targeting the ABL Myristoyl Pocket），結合在肉豆蔻醯結合口袋，屬變構（allosteric）抑制。
傳統 TKI（imatinib、dasatinib、nilotinib、bosutinib、ponatinib）則競爭 ATP 結合位。
機轉不同，所以抗藥突變譜也不同。
#血液專科
https://hema-2026.hsiehting.com/q/114-031
August 3, 2026 at 8:32 AM
Asciminib 的機轉定位
它是 STAMP 抑制劑（Specifically Targeting the ABL Myristoyl Pocket），結合在肉豆蔻醯結合口袋，屬變構（allosteric）抑制。
傳統 TKI（imatinib、dasatinib、nilotinib、bosutinib、ponatinib）則競爭 ATP 結合位。
機轉不同，所以抗藥突變譜也不同。
#血液專科
https://hema-2026.hsiehting.com/q/114-031
它是 STAMP 抑制劑（Specifically Targeting the ABL Myristoyl Pocket），結合在肉豆蔻醯結合口袋，屬變構（allosteric）抑制。
傳統 TKI（imatinib、dasatinib、nilotinib、bosutinib、ponatinib）則競爭 ATP 結合位。
機轉不同，所以抗藥突變譜也不同。
#血液專科
https://hema-2026.hsiehting.com/q/114-031
🎧 On this episode of #OncLiveOnAir, Jorge Cortes, MD, and Elias Jabbour, MD, discuss the orally disintegrating tablet formulation of nilotinib and its June 2026 @fda.gov approval for patients with CML. @mdanderson.bsky.social #leusm #hematology #oncology
www.onclive.com/view/fda-app...
www.onclive.com/view/fda-app...
July 28, 2026 at 1:00 AM
🎧 On this episode of #OncLiveOnAir, Jorge Cortes, MD, and Elias Jabbour, MD, discuss the orally disintegrating tablet formulation of nilotinib and its June 2026 @fda.gov approval for patients with CML. @mdanderson.bsky.social #leusm #hematology #oncology
www.onclive.com/view/fda-app...
www.onclive.com/view/fda-app...
Online now: Nilotinib induces immunogenic cuproptosis to potentiate cancer immunotherapy
Nilotinib induces immunogenic cuproptosis to potentiate cancer immunotherapy
Yao et al. identify nilotinib, an FDA-approved anti-tumor drug, as a non-ionophore immunogenic cuproptosis inducer that potentiates anti-PD-1 immunotherapy. Mechanistically, nilotinib-copper represses ATP7A via ETV1 to drive mitochondrial copper accumulation and activates ERK2 phosphorylation to potentiate cuproptosis.
dlvr.it
July 27, 2026 at 12:27 PM
Online now: Nilotinib induces immunogenic cuproptosis to potentiate cancer immunotherapy
A paper using RRID:AB_2062045 from @proteintech.bsky.social was just published in Cell Reports Medicine. Thanks for making your methods matter! #STMpublishing #OpenScience #methodsmatter
Nilotinib induces immunogenic cuproptosis to potentiate cancer immunotherapy
Read the full paper: Nilotinib induces immunogenic cuproptosis to potentiate cancer immunotherapy
doi.org
July 24, 2026 at 7:00 AM
A paper using RRID:AB_2062045 from @proteintech.bsky.social was just published in Cell Reports Medicine. Thanks for making your methods matter! #STMpublishing #OpenScience #methodsmatter
WATCH 👀: Elias Jabbour, MD, of @mdanderson.bsky.social discusses the significance of the @fda.gov approval of orally disintegrating nilotinib tablets for chronic myeloid leukemia.
See the whole video here➡️: onclive.com/view/dr-jabb...
#oncology #leusm
See the whole video here➡️: onclive.com/view/dr-jabb...
#oncology #leusm
July 13, 2026 at 8:18 PM
WATCH 👀: Elias Jabbour, MD, of @mdanderson.bsky.social discusses the significance of the @fda.gov approval of orally disintegrating nilotinib tablets for chronic myeloid leukemia.
See the whole video here➡️: onclive.com/view/dr-jabb...
#oncology #leusm
See the whole video here➡️: onclive.com/view/dr-jabb...
#oncology #leusm
Ο ΕΟΦ ανακαλεί παρτίδα φαρμάκου για τη λευχαιμία
Ο ΕΟΦ ανακαλεί παρτίδα φαρμάκου για τη λευχαιμία
Ο ΕΟΦ ανακάλεσε σήμερα (18/6) παρτίδα ιατρικού φαρμάκου που λαμβάνεται για τη θεραπεία της λευχαιμίας, καθώς δεν αποτελεί τις απαραίτητες προδιαγραφές. Συγκεκριμένα ο ΕΟΦ ανακαλεί την παρτίδα H0444C με ημερ. λήξης 07/2027 του φαρμάκου NILOTINIB TEVA caps 200mg/cap BT x 112. Η ανακοίνωση του ΕΟΦ «Την
lawandorder.gr
June 18, 2026 at 3:40 PM
Ο ΕΟΦ ανακαλεί παρτίδα φαρμάκου για τη λευχαιμία
This is what progress looks like.
The #FDA approved a new dissolvable form of nilotinib for adults with Ph+ CML. No water. No food restrictions. No timing concerns around other medications.
More flexibility built into daily treatment. That matters.
Full story ⬇️
The #FDA approved a new dissolvable form of nilotinib for adults with Ph+ CML. No water. No food restrictions. No timing concerns around other medications.
More flexibility built into daily treatment. That matters.
Full story ⬇️
FDA Approves a Patient-Friendly, Dissolvable Therapeutic for Chronic Myeloid Leukemia | Blood Cancer United
The dissolvable format may also benefit individuals who have difficulty swallowing pills, offering greater flexibility and ease of use.
bloodcancerunited.org
June 16, 2026 at 9:37 PM
This is what progress looks like.
The #FDA approved a new dissolvable form of nilotinib for adults with Ph+ CML. No water. No food restrictions. No timing concerns around other medications.
More flexibility built into daily treatment. That matters.
Full story ⬇️
The #FDA approved a new dissolvable form of nilotinib for adults with Ph+ CML. No water. No food restrictions. No timing concerns around other medications.
More flexibility built into daily treatment. That matters.
Full story ⬇️
🚨 BREAKING 🚨: The @fda.gov has approved an orally disintegrating tablet formulation of nilotinib for select patients with CML #leusm #hematology #oncology
www.onclive.com/view/fda-app...
www.onclive.com/view/fda-app...
June 2, 2026 at 4:23 PM
🚨 BREAKING 🚨: The @fda.gov has approved an orally disintegrating tablet formulation of nilotinib for select patients with CML #leusm #hematology #oncology
www.onclive.com/view/fda-app...
www.onclive.com/view/fda-app...
Nilotinib 200mg Price for Nigeria Supplier & Wholesale - Oddway
www.oddwayinternational.com/nilotinib-20...
#Dzień #Miłego 破滅リ Günaydın Dnia Någon Мир Видимо Diliyorum
오늘은 상태가 많아서 Καλημέρα 받은 빠르게 #Vostro 걸로 남자 Таким #health #healthcare #bulk #wholesale #nigeria #africa #medicine #b2b
www.oddwayinternational.com/nilotinib-20...
#Dzień #Miłego 破滅リ Günaydın Dnia Någon Мир Видимо Diliyorum
오늘은 상태가 많아서 Καλημέρα 받은 빠르게 #Vostro 걸로 남자 Таким #health #healthcare #bulk #wholesale #nigeria #africa #medicine #b2b
May 28, 2026 at 7:28 AM
Nilotinib 200mg Price for Nigeria Supplier & Wholesale - Oddway
www.oddwayinternational.com/nilotinib-20...
#Dzień #Miłego 破滅リ Günaydın Dnia Någon Мир Видимо Diliyorum
오늘은 상태가 많아서 Καλημέρα 받은 빠르게 #Vostro 걸로 남자 Таким #health #healthcare #bulk #wholesale #nigeria #africa #medicine #b2b
www.oddwayinternational.com/nilotinib-20...
#Dzień #Miłego 破滅リ Günaydın Dnia Någon Мир Видимо Diliyorum
오늘은 상태가 많아서 Καλημέρα 받은 빠르게 #Vostro 걸로 남자 Таким #health #healthcare #bulk #wholesale #nigeria #africa #medicine #b2b
Zoomlab™-guided co-crystal engineering of nilotinib for improved dissolution https://www.tandfonline.com/doi/full/10.1080/10837450.2026.2624727?af=R
May 23, 2026 at 10:52 AM
Zoomlab™-guided co-crystal engineering of nilotinib for improved dissolution https://www.tandfonline.com/doi/full/10.1080/10837450.2026.2624727?af=R
BCR-ABL1 inhibitors transformed CML/Ph+ ALL therapy. Imatinib binds inactive ABL (DFG-out) but is mutation-sensitive. Dasatinib binds active form, higher potency, less selective. Nilotinib improves affinity yet misses T315I. Bosutinib targets SRC/ABL, better safety, limited T315I efficacy.
March 28, 2026 at 7:19 AM
BCR-ABL1 inhibitors transformed CML/Ph+ ALL therapy. Imatinib binds inactive ABL (DFG-out) but is mutation-sensitive. Dasatinib binds active form, higher potency, less selective. Nilotinib improves affinity yet misses T315I. Bosutinib targets SRC/ABL, better safety, limited T315I efficacy.
An important study in observance of #DVT Awareness Month! It concluded that Dasatinib, ponatinib, and nilotinib damage ECs in different ways, all of which can contribute to #arterialthrombosis. Read the full article in Blood VTH: ashpublications.org/bloodvth/art... #BloodVTH
March 24, 2026 at 8:02 PM
An important study in observance of #DVT Awareness Month! It concluded that Dasatinib, ponatinib, and nilotinib damage ECs in different ways, all of which can contribute to #arterialthrombosis. Read the full article in Blood VTH: ashpublications.org/bloodvth/art... #BloodVTH
Find Price For Generic Nilotinib Brands In India - Oddway
www.oddwayinternational.com/nilotinib-20...
#BBB26 #이거 #Jonas #LFI #Günaydın #ForaJonas #Lorde #좋겠다 #Brasil #BBB #Jospin #Lionel #LFI #Lunes #Municipales #Matin #Socialiste #Campagne #Jean #Résultats #health #pharmacy #cancer #Leukemia
www.oddwayinternational.com/nilotinib-20...
#BBB26 #이거 #Jonas #LFI #Günaydın #ForaJonas #Lorde #좋겠다 #Brasil #BBB #Jospin #Lionel #LFI #Lunes #Municipales #Matin #Socialiste #Campagne #Jean #Résultats #health #pharmacy #cancer #Leukemia
March 23, 2026 at 9:08 AM
Find Price For Generic Nilotinib Brands In India - Oddway
www.oddwayinternational.com/nilotinib-20...
#BBB26 #이거 #Jonas #LFI #Günaydın #ForaJonas #Lorde #좋겠다 #Brasil #BBB #Jospin #Lionel #LFI #Lunes #Municipales #Matin #Socialiste #Campagne #Jean #Résultats #health #pharmacy #cancer #Leukemia
www.oddwayinternational.com/nilotinib-20...
#BBB26 #이거 #Jonas #LFI #Günaydın #ForaJonas #Lorde #좋겠다 #Brasil #BBB #Jospin #Lionel #LFI #Lunes #Municipales #Matin #Socialiste #Campagne #Jean #Résultats #health #pharmacy #cancer #Leukemia